Perioperative medicine & outcomes

Prognostic value of perioperative changes in serum primary metabolites in patients after major surgery under general anesthesia: an exploratory secondary analysis of the TAPIR trial

Can J AnaesthPublished Secondary analysis of the TAPIR randomised trial

Authors' conclusion

Major abdominal surgery under general anesthesia was associated with complex changes in primary metabolites. We identified alterations in certain metabolites that were associated with postoperative delirium.

Study context

Population
High-risk patients undergoing major abdominal surgery under GA
Participants
177 patients
Comparison
Serum primary metabolites on POD3 vs before surgery
Primary endpoint
Postoperative alterations in primary serum metabolites
Follow-up
POD3
Methodological detailsexploratory, targeted metabolomic analysis, false discovery rate-adjusted P values
  • Exploratory
  • Targeted metabolomic analysis
  • False discovery rate-adjusted P values

Primary result

As reported in the abstract

Primary serum metabolites, POD3 vs before surgery
Metabolites different on POD3 vs before surgery (of 37 analysed)
20

Secondary outcomes

Preoperative metabolites, patients with vs without postoperative complications (subgroup)

No statistically significant preoperative differences
  • All adjusted P values ≥ 0.05

Postoperative metabolites, patients with vs without delirium within 30 days (subgroup)

Patients with delirium
13/177
Lower alanine, asparagine, citrulline, cystine, glutamine, glutamic acid, serine, threonine, tyrosine with delirium, adjusted for preoperative levels

Original publication

Prognostic value of perioperative changes in serum primary metabolites in patients after major surgery under general anesthesia: an exploratory secondary analysis of the TAPIR trial. Can J Anaesth. Published 30 June 2025. doi:10.1007/s12630-025-02984-6

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.